Dr. Gail Farfel is an accomplished life sciences executive and neuroscientist who currently serves on the boards of the Dravet Syndrome Foundation, DURECT Corporation, and the American Society for Experimental Neurotherapeutics (ASENT). She was previously Chief Executive Officer of ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases. Dr. Farfel brings deep industry experience, having held senior leadership roles at Zogenix, Marinus Pharmaceuticals, Novartis Pharmaceuticals, and Pfizer. She also served on the boards of AVROBIO and the University of Chicago Medical & Biological Sciences Alumni Association.  With over 50 scientific publications and presentations in the fields of neuropsychopharmacology and drug effects, Dr. Farfel is a globally recognized thought leader in neuroscience research. She earned her bachelor’s degree in biochemistry from the University of Virginia and holds a PhD in neuropsychopharmacology from the University of Chicago.